Newsbenzinga
Seaport Therapeutics' GlyphAgo Phase 1 MAD Data Shows Favorable Safety And Tolerability, Advancing Into Two Phase 2 GAD Trials
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Comments —
Loading comments…